Submitted by WallStArb on Fri, 05/11/2012 - 8:50am
Attached is a PDF of most of the small/mid cap biotech and their current cash situation. As a RULE it's unwise to invest in a company that won't be around in the near future or has a dire need to secure financing. Many times it's possible to find companies who's lead product might have failed or had bad data and the stock collapses.
Submitted by WallStArb on Wed, 03/21/2012 - 5:51pm
I have followed and invested in TINY many times over the years - especially when this company is going into a potential upswing in IPO activity. After looking at their 10K released a week ago the following nugget was stealthily mentioned.
Submitted by WallStArb on Fri, 02/17/2012 - 3:05pm
In an earlier blog I mentioned that Abraxane by CELG had some great data and in my opinion is teh yardstick that TH-302 and THLD will be compared. There's an interesting way to play JUST that drug without having to buy all of CELG.
Through CELGZ which is a CVR (contingent value right) you get all of the potential monetary gains of Abraxane - which was acquired when Celgene bought Abraxis.
Recent comments